Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:38 PM
Ignite Modification Date:
2025-12-24 @ 2:38 PM
NCT ID:
NCT00373659
Eligibility Criteria:
Inclusion Criteria:
* Age 50 years or older
* Active primary or recurrent macular neovascularization secondary to age-related macular degeneration (AMD) involving the central fovea in the study eye with evidence of disease progression
* OCT central retinal thickness ≥ 300 microns
* Best corrected visual acuity, using ETDRS charts, of 20/40 to 20/400 (Snellen equivalent) in the study eye
Exclusion Criteria:
* More than 3 prior treatments with verteporfin photodynamic therapy
* Previous participation in a clinical trial (for either eye) involving antiangiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors)
* Previous subfoveal focal laser photocoagulation in the study eye
* Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding day 0
* Subfoveal fibrosis or atrophy in the study eye
* History of vitrectomy surgery in the study eye
* Aphakia or absence of the posterior capsule in the study eye
* History of idiopathic or autoimmune-associated uveitis in either eye
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
50 Years
Study:
NCT00373659
Study Brief:
Protocol Section:
NCT00373659